Inhibition of PD-1/PD-L1 ligation on T-lymphocytes by nivolumab led to T-lymphocyte activation and subsequently gave rise to T-lymphocyte-mediated autoimmune cardiomyopathy. Here, PDCD1 is linked to autoimmune cardiomyopathy.